YKT6 expression, exosome release, and survival in non-small cell lung cancer

Marc Ruiz-Martinez; Alfons Navarro; Ramón M. Marrades; Nuria Viñolas; Sandra Santasusagna; Carmen Muñoz; Josep Ramírez; Laureano Molins; Mariano Monzo

doi:10.18632/oncotarget.9862

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

YKT6 expression, exosome release, and survival in non-small cell lung cancer

Marc Ruiz-Martinez, Alfons Navarro, Ramón M. Marrades, Nuria Viñolas, Sandra Santasusagna, Carmen Muñoz, Josep Ramírez, Laureano Molins and Mariano Monzo _

PDF | HTML | How to cite

Oncotarget. 2016; 7:51515-51524. https://doi.org/10.18632/oncotarget.9862

Metrics: PDF 2155 views | HTML 4643 views | ?

Abstract

Marc Ruiz-Martinez1, Alfons Navarro1, Ramón M. Marrades2, Nuria Viñolas3, Sandra Santasusagna1, Carmen Muñoz1, Josep Ramírez4, Laureano Molins5, Mariano Monzo1

1Molecular Oncology and Embryology Laboratory, Department of Human Anatomy and Embryology, School of Medicine, University of Barcelona, IDIBAPS, Barcelona, Spain

2Department of Pneumology, Institut Clínic del Tórax (ICT), Hospital Clinic de Barcelona, University of Barcelona, IDIBAPS, CIBER de Enfermedades Respiratorias (CIBERES), Barcelona, Spain

3Department of Medical Oncology, Institut Clinic Malalties Hemato-Oncològiques (ICMHO), Hospital Clinic de Barcelona, University of Barcelona, IDIBAPS, Barcelona, Spain

4Department of Pathology, Centro de Diagnóstico Biomédico (CDB), Hospital Clinic de Barcelona, University of Barcelona, IDIBAPS, CIBERES, Barcelona, Spain

5Department of Thoracic Surgery, Institut Clínic del Tórax (ICT), Hospital Clinic de Barcelona, University of Barcelona, Barcelona, Spain

Correspondence to:

Mariano Monzo, email: [email protected]

Keywords: YKT6, exosomes, NSCLC, miR-134, miR-135b

Received: February 11, 2016 Accepted: May 19, 2016 Published: June 06, 2016

ABSTRACT

Background: Cancer-derived exosomes are involved in metastasis. YKT6 is a SNARE protein that participates in the regulation of exosome production and release, but its role in non-small cell lung cancer (NSCLC) has not been examined.

Materials and Methods: Ultracentrifugation-purified exosomes from the A549 cell line were studied by CRYO-TEM, nanoparticle tracking analysis and western blot (TSG101 marker). YKT6 was inhibited using a DsiRNA and selected pre-microRNAs. MicroRNAs targeting YKT6 were validated by Renilla/Luciferase assay and western blot. YKT6 expression and its prognostic impact were analyzed in 98 tissue specimens from resected NSCLC patients.

Results: Membranous nanosized vesicles (mode size: 128nm) with TSG101 protein were purified from A549 cells. YKT6 inhibition reduced exosome release by 80.9%. We validated miR-134 and miR-135b as miRNAs targeting YKT6, and transfection with the pre-miRNAs also produced a significant reduction in exosome release. The analysis of YKT6 in tumor samples showed that patients with high levels had shorter disease-free and overall survival.

Conclusions: YKT6 is a key molecule in the regulation of exosome release in lung cancer cells and is in turn precisely regulated by miR-134 and miR-135b. Moreover, YKT6 levels impact prognosis of resected NSCLC patients.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 9862

Publication Alerts

Research Papers:

YKT6 expression, exosome release, and survival in non-small cell lung cancer

Abstract